Letters Trial of amiodarone for Ebola

Concerns about the off-licence use of amiodarone for Ebola

BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h272 (Published 20 January 2015) Cite this as: BMJ 2015;350:h272
  1. Ankur Gupta-Wright, academic clinical fellow in infectious diseases1,
  2. James Lavers, intensive care specialist registrar2,
  3. Sharon Irvine, clinical fellow (infectious diseases)3
  1. 1Department of Clinical Research, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
  2. 2Ysbyty Gwynedd, Bangor, UK
  3. 3Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK
  1. ankurgw{at}outlook.com

We were disturbed by your article promoting the compassionate use of amiodarone for Ebola virus disease by the non-governmental organisation (NGO), Emergency, which suggested its use was endorsed by the Department for International Development and WHO.1 …

View Full Text

Log in

Log in through your institution


* For online subscription